Cellsonics Inc.

Cellsonics Inc. specializes in advanced tissue dissociation technology, providing solutions that enhance biological research efficiency while preserving cell integrity. Their innovative SimpleFlow TM system is designed for high-yield, viable single-cell suspensions. Cellsonics Inc.

is dedicated to advancing tissue dissociation solutions. The company was co-founded by Steve Levers and Vibhu Vivek. Headquartered in San Jose, US, Cellsonics secured venture funding from Wavemaker Three-Sixty Health in June 2019. Steve Levers, the CEO, has a history of involvement in technology and biotech innovations.

Cellsonics specializes in advanced tissue dissociation technology, prominently featuring its flagship product, SimpleFlow TM. This innovative system utilizes acoustic wave technology to dissociate biological tissues without the use of enzymes, thus preserving the integrity of sensitive cell types. By avoiding traditional enzymatic methods, SimpleFlow enables the generation of high-yield, viable single-cell suspensions that maintain the native populations of cells present prior to dissociation. The primary end users of this technology include researchers and laboratories in the fields of cellular biology, tissue engineering, and regenerative medicine, who seek to obtain more representative cell populations for high-throughput analysis.

Cellsonics markets its products primarily to academic research institutions and biotech firms in North America, Europe, and parts of Asia, catering to a growing demand for advanced cell dissociation solutions. Cellsonics generates revenue through the sale of its SimpleFlow TM systems and related consumables to institutional customers, primarily within the research and biotechnology sectors. The company operates on a direct sales model, engaging with academic institutions, pharmaceutical companies, and life sciences research organizations to fulfill their tissue dissociation needs. Typical transactions involve the outright purchase of the SimpleFlow device, complemented by ongoing sales of consumables necessary for its operation.

While specific pricing details for these products are not disclosed, the revenue structure is likely bolstered by the need for repeat purchases of consumables, enhancing customer retention and continuous revenue flow. The emphasis on product innovation and scientific collaboration positions Cellsonics favorably within its market, thereby facilitating sustained growth and engagement with its client base. Cellsonics Inc. plans to utilize the funding raised in June 2019 to further enhance its product offerings and expand its market reach.

Upcoming products are being designed to improve the efficiency of tissue dissociation while maintaining cell viability. The company is targeting expansion into European and Asian markets by 2025, aiming to establish partnerships with local research institutions and biotech firms. The recent funding will support the research and development of these new products as well as marketing efforts to penetrate these new geographic regions.